Frequently Asked Questions
How can we help you?
AI supports development of a directional ‘starter’ model to support users to begin the process of building a model that is credible, robust, and customized to their technology.
The field of health economics is quite standardized in terms of interpretation of results of analyses of health economic models, and decisions recommended to be made. AI is able to support users to interpret results and articulate their value story.
Yes. The platform has guidance and support, with experts available upon request, that enables those not familiar with health economics to build a robust model.
Calibrayt has a grading system that provides real-time assessment of model credibility/robustness, with full transparency to audiences viewing analytic outputs when presented.
Calibrayt supports a wide range of analyses of health economic models, including cost-effectiveness analysis, scenario analysis, sensitivity analysis, threshold analysis, and budget impact analysis. Each analytic category has its own unique insights, and the platform supports users with interpretation to enable effective communication of the technology value story.
Fortunately, the field of health economics is quite standardized, and Calibrayt has analytic modules that both recommend and run pre-specified analytics, producing insightful graphs and tables, along with their interpretation, without requiring users to complete any data analytics.
Early assessment of value supports innovators to make informed strategic and foundational decisions, for example the most attractive patient segments (e.g., stage of disease) and the economic drivers of technology value sufficient to inform technology trial design and data collection. Further, key audiences of early-stage companies require evidence that the technology is likely to be attractive to those intended to pay for it, as well as the commercially acceptable pricing power.
Technology effectiveness can be credibly estimated. Calibrayt provides methods and advice to do this, helping companies to understand their potential health economics and value story, and in fact can support identification of the required effectiveness or other eventual technology trial result in order to achieve a desired value-based price.
A health economic model is a working tool. It supports innovators with early discovery of their commercial potential, most valuable aspects of their value proposition, value-based pricing range, and likely attractiveness or Adoption Case from the perspective of the intended payer. Model development is an ongoing process, with new data and information being available over time, for example from technology trial or with the entry of a new competitor or a adoption of a new standard of care as therapeutics enter the market. As companies mature, economic models guide technology trial planning, ensuring that critical health economic data is collected alongside clinical data, such that evidence of the impact of the key technology value drivers is available to support market access success.
Calibrayt provides a mechanism for early-stage innovators to build and analyze their own health economic model, in order to understand and present their Value Story and work with the model over time to inform evolving decisions with technology and company maturity. ASSESS connects innovators of all stages to experts in health technology assessment and health economics for expert-led point-in-time analyses and reporting, when a full-service analytic solution is desired.
Currently, Calibrayt supports the majority of health economic analysis needs, including through the use of decision trees and Markov modelling.
Calibrayt will guide model selection. Decision Trees are typically used when there isn’t a need to follow patients for a significant amount of time, in which case a Markov model is utilized.